Efficacy of Delayed Granulocyte Colony-Stimulating Factor after Full Dose CHOP Therapy in Non-Hodgkin's Lymphoma: A Pilot Study for a Leukocyte Count Oriented Regimen

References

• Armitage J. O., Corder M. P., Leimert J. T. Advanced diffuse histiocytic lymphoma treated with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) without maintenance therapy. Cancer Treat. Rep. 1980; 64: 649–654
   PubMedGoogle Scholar
• Coltman C. A., Dahlberg J., Jones S. E. CHOP is curative in thirty percent of patients with diffuse large cell lymphoma: a twelve year South West Oncology Group Follow Up. Proc. Nat. Acad. Sci. USA 1986; 5, 774 (abstr)
   Google Scholar
• McKelvey E. M., Gottlieb J. A., Wilson H. E. Hydroxyldaunomycin (adriamycin) combination chemotherapy in malignant lymphoma. Cancer 1976; 38: 1484–1493
   PubMed Web of Science ®Google Scholar
• Coleman M. Chemotherapy for large-cell lymphoma: optimism and caution. Ann. Int. Med. 1985; 103: 140–142
   PubMed Web of Science ®Google Scholar
• Shipp M. A., Harrington D. P., Klatt M. M., Jochelson M. S., Pinkus G. S., Marshall J. L., Rosenthal D. S., Skarin A. T., Ganellos G. P. Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD. Ann. Int. Med. 1986; 104: 757–765
   PubMed Web of Science ®Google Scholar
• Fisher R. I., Devita V. T., Hubbard S. M. Randomized trial of ProMACE-MOPP vs. ProMACE-CytaBOM in previously untreated, advanced stage, diffuse aggressive lymphomas. Proc. Am. Soc. Clin. Oncol. 1984; 3: 242
   Google Scholar
• Klimo P., Connors J. M. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann. Int. Med. 1985; 102: 596–602
   PubMed Web of Science ®Google Scholar
• Fisher R. I., Gaynor E. R., Dahlberg S., Oken M. M., Grogan T. M., Mize E. M., Glick J. H., Coltman C. A., Miller T. P. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. New Engl. J. Med. 1993; 328: 1002–1006
   PubMed Web of Science ®Google Scholar
• Duhrsen U., Villeval J. L., Boyd J., Kannourakis G., Morstyn G., Metcalf D. Effects of recombinant human granulocyte colony stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 1988; 72: 2074–2081
   PubMed Web of Science ®Google Scholar
• Neidhart J. A. Hematopoietic colony-stimulating factors. Uses in combination with standard chemotherapeutic regimens and in support of dose intensification. Cancer 1992; 70, (suppl), 913–920
   PubMed Web of Science ®Google Scholar
• Demuynck H., Pettengell R., De Campos E., Dexter T. M., Testa N. G. The capacity of peripheral blood stem cells mobilized with chemotherapy plus G-CSF to repopulate irradiated marrow stroma in vitro is similar to that of bone marrow. Eur. J. Cancer 1992; 28: 381–386
   PubMed Web of Science ®Google Scholar
• Teshima T., Harada M., Takamatsu Y., Makino K., Taniguchi S., Inaba S., Kondo S., Tanaka T., Akashi K., Minamishima I. Cytotoxic drug and cytotoxic drug/G-CSF mobilization of peripheral blood stem cells and their use for autografting. Bone Marrow Transplant. 1992; 10: 215–220
   PubMed Web of Science ®Google Scholar
• Hohaus S., Goldschmidt H., Ehrhardt R., Haas R. Successful autografting following myeloablative conditioning therapy with blood stem cells mobilized by chemotherapy plus rhG-CSF. Exper. Hematol. 1993; 21: 508–514
   PubMed Web of Science ®Google Scholar
• Pettengell R., Testa N. G., Swindell R., Crowther D., Dexter T. M. Transplantation potential of hematopoietic cells released into the circulation during routine chemotherapy for non-Hodgkin's lymphoma. Blood 1993; 82: 2239–2248
   PubMed Web of Science ®Google Scholar
• Hryniuk W. M. The importance of dose intensity in outcome of chemotherapy. Importance Advances in Oncology, S. Hellman, V. Devita, S. (eds.). Rosenberg, 1988; 121–141
   Google Scholar
• Metcalf D. Control of granulocytes and macrophages: molecular, cellular, and clinical aspects. Science 1991; 254: 529–533
   PubMed Web of Science ®Google Scholar
• The non-Hodgkin's lymphoma pathologic classification project. National cancer institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. Cancer 1982; 49: 2112–2135
   PubMed Web of Science ®Google Scholar
• Carbone P. P., Kaplan H. S., Musshoff K., Smithers D. W., Tubiana M. Report of the committee on Hodgkin's disease staging classification. Cancer Res. 1971; 31: 1860–1861
   PubMed Web of Science ®Google Scholar
• Tsakona C. P., Khwaja A., Goldstone A. H. Does treatment with haemopoietic growth factors affect the incidence of bacteraemia in adult lymphoma transplant recipients?. Bone Marrow Transplant. 1993; 11: 433–436
   PubMed Web of Science ®Google Scholar
• Hovgaard D. J., Nissen N. I. A phase I/II study of dose and administration of non-glycosylated bacterially synthesized G-M CSF in chemotherapy-induced neutropenia in patients with non-Hodgkin's lymphomas. Leukemia and Lymphoma 1992; 7: 217–224
   PubMed Web of Science ®Google Scholar
• Hovgaard D. J., Nissen N. I. Effect of recombinant human granulocyte-macrophage colony-stimulating factor in patients with Hodgkin's disease: A phase I/II study. J. Clin. Oncol. 1992; 10: 390–397
   PubMed Web of Science ®Google Scholar
• Pettengell R., Gurney H., Radford J. A., Deakin D. P., James R., Wilkinson P. M., Kane K., Bentley J., Crowther D. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: A randomized controlled trial. Blood 1992; 80: 1430–1436
   PubMed Web of Science ®Google Scholar
• Gulati S. C., Bennett C. L. Granulocyte-macrophage colony-stimulating factor (GM-CSF) as adjunct therapy in relapsed Hodgkin disease. Ann. Int. Med. 1992; 116: 177–182
   PubMed Web of Science ®Google Scholar
• Gianni A. M., Bregni M., Siena S., Magni M., Di-Nicola M., Lombardi F., Tarella C., Pileri A., Bonadonna G. Granulocyte-macrophage colony-stimulating factor or granulocyte colony-stimulating factor infusion makes high-dose etoposide a safe outpatient regimen that is effective in lymphoma and myeloma patients. J. Clin. Oncol. 1992; 10: 1955–1962
   PubMed Web of Science ®Google Scholar
• Ikebuchi K., Ihle J. N., Hirai Y., Wong G. G., Clark S. C., Ogawa M. Synergistic factors for stem cell proliferation: further studies of the target stem cells and the mechanism of stimulation by IL-1, IL-6, and G-CSF. Blood 1988; 72: 2007–2014
   PubMed Web of Science ®Google Scholar
• Morstyn G., Campbell L., Lieschke G. J., Layton J. E., Maher D., O'Connor M., Green M., Sheridan W., Vincent M., Alton K. Abrogation of chemotherapy induced neutropenia by subcutaneously administered granulocyte colony-stimulating factor with optimization of dose and duration of therapy. J. Clin. Oncol. 1989; 7: 1554–1562
   PubMed Web of Science ®Google Scholar
• Khwaja A., Mills W., Leveridge K., Goldstone A. H., Linch D. C. Efficacy of delayed granulocyte colony-stimulating factor after autologous BMT. Bone Marrow Transplant. 1993; 11: 479–482
   PubMed Web of Science ®Google Scholar
• Meisenberg B. R., Davis T. A., Melaragno A. J., Stead R., Monroy R. L. A comparison of therapeutic schedules for administering granulocyte colony-stimulating factor to non-human primates after high-dose chemotherapy. Blood 1992; 79: 2267–2272
   PubMed Web of Science ®Google Scholar